Peptide hormones

Insulet to Announce First Quarter 2021 Financial Results on May 6, 2021

Retrieved on: 
Monday, April 5, 2021
Biotechnology, Diabetes, Health, Medical devices, Clinical medicine, Medicine, Branches of biology, Peptide hormones, Recombinant proteins, Insulin pump, Insulin, Tubeless tire

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the first quarter of 2021 on May 6, 2021 after the close of the financial markets.

Key Points: 
  • Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced plans to release its financial results for the first quarter of 2021 on May 6, 2021 after the close of the financial markets.
  • In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
  • You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 6966926.
  • Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

The Fast Way to a Safe Insulin Pen

Retrieved on: 
Tuesday, March 30, 2021
Clinical medicine, Medicine, Branches of biology, Peptide hormones, Recombinant proteins, Insulin, Diabetes, Injector pen

"We have installed more than 100 servo press kits in the automated assembly lines for insulin pens," said Ulrik Keldke, Head of Syntegon's engineering department.

Key Points: 
  • "We have installed more than 100 servo press kits in the automated assembly lines for insulin pens," said Ulrik Keldke, Head of Syntegon's engineering department.
  • "Automating the assembly line is a prerequisite for meeting the requirements for the end product: the insulin pens must be safe and user-friendly," said Andersen.
  • "The automated systems ensure that the insulin pens are always in order and can deliver the exact amount of insulin."
  • The assembly line for insulin pens can be expanded into a complete line with other systems from the company.

Glytec Releases New Innovations for Inpatient Insulin Therapy, Further Uniting Teams Around Patient Safety

Retrieved on: 
Tuesday, March 30, 2021
Software, Managed care, Health, Diabetes, Medical devices, Data management, Hospitals, Technology, Clinical medicine, Medical specialties, Branches of biology, Peptide hormones, Recombinant proteins, Health care quality, Patient safety, Insulin, Glucommander, Workflow

To date, more than 90 research studies have validated the safety and efficacy of Glytecs insulin management software.

Key Points: 
  • To date, more than 90 research studies have validated the safety and efficacy of Glytecs insulin management software.
  • With Glucommanders 3.5.1.0 Medication Confirmation and Order Integration release, Glytec is introducing enhancements and integrations that expand on and strengthen the companys 15-year commitment to innovation and patient safety with new features.
  • For the past 15 years, Glytec has been at the forefront of developing computer-guided algorithms that make personalized insulin dosing possible.
  • These latest enhancements are just the most recent example of our ongoing commitment to patient safety and improving nursing workflows.

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure

Retrieved on: 
Friday, March 26, 2021
Peptides, Aviptadil, Peptide hormones, Vasoactive intestinal peptide, Vasoactivity, Peptide, Hormones, Branches of biology, Organ systems

RADNOR, Pa., March 26, 2021 /PRNewswire/ --NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 respiratory failure ( www.clinicaltrials.gov 04311697).

Key Points: 
  • RADNOR, Pa., March 26, 2021 /PRNewswire/ --NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 respiratory failure ( www.clinicaltrials.gov 04311697).
  • A conference call will be held at 8:30am EDT on Monday, March 29th with attendance from corporate leadership and lead investigators.
  • NeuroRx, Inc. has signed an agreement to merge with Big Rock Partners Acquisition Corp.
  • Details may be viewed at http://irdirect.net/filings/viewer/index/1719406/000119312521019278
    Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970.

HumanN Launches New SuperBeets® Memory & Focus Chews to Support Brain Health

Retrieved on: 
Thursday, March 25, 2021
Branches of biology, Developmental neuroscience, Growth factors, Neurotrophic factors, Peptide hormones, Neurochemistry, Brain-derived neurotrophic factor, Brain, Resveratrol

SuperBeetsMemory & Focus is a unique supplement that contains clinically-studied polyphenol compounds to support two aspects of brain health: brain blood flow and BDNF.

Key Points: 
  • SuperBeetsMemory & Focus is a unique supplement that contains clinically-studied polyphenol compounds to support two aspects of brain health: brain blood flow and BDNF.
  • Blood flow to the brain, along with Brain-Derived Neurotrophic Factor (BDNF) - a key protein found in the brain - are important in promoting overall cognitive health.
  • SuperBeetsMemory & Focus features a highly pure form of Resveratrol produced through a unique fermentation process, along with a patented coffee fruit extract that have been clinically shown to help promote brain blood flow and support brain health, respectively.
  • Humann'sfull catalog of products, including the new SuperBeets Memory & Focus Chews is available online and on Amazon.

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol

Retrieved on: 
Tuesday, March 23, 2021
Drugs, Clinical medicine, Medicine, Peptide hormones, Recombinant proteins, Insulin, Medroxyprogesterone acetate

Efficacy data for the studies will become available after all patients have completed the first 6-month treatment period.

Key Points: 
  • Efficacy data for the studies will become available after all patients have completed the first 6-month treatment period.
  • "With both concurrent Phase 3 studies now enrolling, we have achieved another world-first milestone, as the only company to conduct two Phase 3 oral insulin studies under an FDA protocol.
  • Oramed Pharmaceuticalsis a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices inthe United StatesandIsrael, Oramed has developed a novel Protein Oral Delivery (POD) technology.

Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes

Retrieved on: 
Monday, March 22, 2021
Organ systems, Clinical medicine, Endocrine system, Peptide hormones, Diabetes, Animal products, Pancreatic hormones, Recombinant proteins, Glucagon, Hypoglycemia, Insulin, Pheochromocytoma

ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

Key Points: 
  • ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
  • ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor.
  • If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously.
  • Zealand markets V-Go, a basal-bolus insulin delivery option for people with diabetes, and has received FDA approval for Zegalogue, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above.

Healthcare Services Leader Ted Bucknam Joins Hygieia as President, Leading Company’s Expansion of Clinical Insulin Management Program

Retrieved on: 
Tuesday, March 23, 2021
Medical devices, Finance, Diabetes, Professional services, Practice Management, Biotechnology, Managed care, General Health, Pharmaceutical, Health, Branches of biology, Clinical medicine, Organ systems, Peptide hormones, Recombinant proteins, Insulin, Endocrinology

Bucknam will spearhead the companys clinical expansion, working with endocrinologists, referring physicians and clinic partners throughout Michigan and the U.S.

Key Points: 
  • Bucknam will spearhead the companys clinical expansion, working with endocrinologists, referring physicians and clinic partners throughout Michigan and the U.S.
  • View the full release here: https://www.businesswire.com/news/home/20210323005209/en/
    Ted Bucknam joins Hygieia as president, in charge of clinical expansion.
  • Ted will guide our expansion with endocrinology clinic partners, enabling their patients to access our revolutionary d-Nav insulin management technology.
  • Hygieia is a specialty provider of insulin therapy and maker of the d-Nav Insulin Management Program.

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

Retrieved on: 
Monday, March 22, 2021
Hormones, Peptide hormones, Branches of biology, Endocrine system, Insulin, Adrenocorticotropic hormone, Pancreatic islets

Crinetics presented a late-breaking e-poster describing the potential of SST5 receptor agonists to regulate glucose-stimulated insulin secretion from human islet cells.

Key Points: 
  • Crinetics presented a late-breaking e-poster describing the potential of SST5 receptor agonists to regulate glucose-stimulated insulin secretion from human islet cells.
  • Based on these preclinical findings, Crinetics advanced CRN04777, an investigational, oral nonpeptide SST5 agonist , into a clinical program for congenital HI.
  • Crinetics also discussed preclinical results related to CRN04894, an investigational, oral nonpeptide ACTH antagonist , during a live oral presentation at ENDO 2021.
  • All presentations made at the annual ENDO 2021 congress may be accessed in the virtual conference environment through April 30, 2021.

World Insulin Delivery Device Market Report 2021: Trends, Forecast, and Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, March 22, 2021
Medical devices, Health, Clinical medicine, Branches of biology, Medicine, Peptide hormones, Recombinant proteins, Insulin, Insulin pump, Insulin analog

The study includes the insulin delivery device market size and forecast for the global insulin delivery device market through 2024, segmented by product type, end user, and region.

Key Points: 
  • The study includes the insulin delivery device market size and forecast for the global insulin delivery device market through 2024, segmented by product type, end user, and region.
  • Some of the features of 'Global Insulin Delivery Devices 2019-2024: Trends, Forecast, and Opportunity Analysis' include:
    Market size estimates: Global insulin delivery device market size estimation in terms of value ($M) shipment.
  • Growth opportunities: Analysis on growth opportunities in different applications and regions for insulin delivery devices in the global insulin delivery device market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, insulin delivery devices in the global insulin delivery device market.